ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02267083
Recruitment Status : Completed
First Posted : October 17, 2014
Results First Posted : January 10, 2018
Last Update Posted : January 10, 2018
Sponsor:
Information provided by (Responsible Party):
Gem Pharmaceuticals

Brief Summary:
This study will assess the safety and efficacy of GPX-150 administered intravenously every 3 weeks in the treatment of patients with soft tissue sarcoma.

Condition or disease Intervention/treatment Phase
Soft Tissue Sarcoma Drug: GPX-150 for Injection Phase 2

Detailed Description:

This is an open-label, single arm study of GPX-150 in patients with soft tissue sarcoma. Approximately 22 patients will be treated in this study. The population for this study is adult patients with histologically proven advanced and/or metastatic malignant soft tissue sarcoma of intermediate or high histologic grade.

All patients who meet all entry criteria will receive GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity or subject withdrawal.

Prior to initiation of treatment, subjects will undergo screening and baseline evaluations. During all study visits, subjects will be evaluated for safety. The dose of GPX-150 may be reduced when subjects meet specified dose reduction safety criteria. Subjects will be evaluated regularly for safety and tolerability. Tumor measurements will be calculated at baseline (within 28 days prior to treatment initiation), then at regular intervals while receiving treatment for up to 1 year. After discontinuing the treatment phase of the study, safety assessments and tumor measurements will be performed 3 weeks after the last dose of study drug.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
Study Start Date : January 7, 2015
Actual Primary Completion Date : November 11, 2015
Actual Study Completion Date : August 18, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: GPX-150
GPX-150 for Injection, 265 mg/m2, every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity, or subject withdrawal.
Drug: GPX-150 for Injection
GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
Other Names:
  • GPX-150
  • 5-imino-13-deoxy-doxorubicin HCl




Primary Outcome Measures :
  1. Number of Subjects Progression-free at 12 Months Per RECIST 1.1 [ Time Frame: 12 months from the beginning of study treatment ]
    The primary efficacy endpoint is the number of patients who were progression-free at 12 months, which is obtained by inversion of the Kaplan-Meier curve for progression-free survival (PFS) at 12 months. Of note, the statistical comparison to historical sarcoma data described in the protocol was not performed due to an enrollment of less than the planned sample size of 30 subjects. Progression is defined using RECIST 1.1, as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).


Secondary Outcome Measures :
  1. Number of Subjects Progression-free at Six Months Per RECIST 1.1 [ Time Frame: 6 months from the beginning of the study treatment ]
    This secondary efficacy endpoint is the progression-free rate (PFR) at 6 months, obtained from the Kaplan-Meier curve for progression-free survival (PFS).

  2. Number of Subjects Experiencing Adverse Events [ Time Frame: From the beginning of study treatment and up to 12 months ]
    Subjects who received at least one dose were included in safety analyses. Adverse events were tabulated by System Organ Class (SOC) and Preferred Term (PT) and coded using MedDRA Version 19.1. Safety and tolerability was determined by frequency, nature, and severity of adverse events and the profile of toxicities.


Other Outcome Measures:
  1. Number of Subjects With Tumor Response Per RECIST 1.1 [ Time Frame: Assessed during screening, then every 6 weeks for the first 24 weeks on study, and then every 9 weeks for the next 24 weeks for up to 1 year. Subjects will be in the study for up to 1 year, or until disease progression or unacceptable toxicity. ]
    Tumor assessments using contrast enhanced computerized tomography (CT) scan of the Chest/Abdomen/Pelvis were performed to assess overall tumor burden. Response rate (RR), where response is defined as complete response (CR), partial response (PR), or stable disease (SD). Determination of CR or PR requires confirmation at the time of the next tumor assessment. An outcome of SD requires at least one assessment 6 weeks after the initiation of dosing. Progression is defined using RECIST 1.1, as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥18 years.
  2. Histological documentation of soft tissue sarcoma (biopsy may be historical and may have been obtained from primary tumor or a metastatic site).
  3. Advanced and/or metastatic malignant soft tissue sarcoma of intermediate or high histologic grade. Excluded are the following sarcoma subtypes:

    • Well-differentiated liposarcoma or atypical lipomatous tumor
    • Embryonal or alveolar rhabdomyosarcoma
    • Ewing sarcoma of soft tissue or bone
    • Gastrointestinal stromal tumor (GIST)
    • Dermatofibrosarcoma protuberans
    • Alveolar soft part sarcoma
    • Solitary fibrous tumor
    • Clear cell sarcoma
    • Kaposi sarcoma
    • Extraskeletal myxoid chondrosarcoma
    • PEComa (perivascular epithelial cell tumor)
    • Myoepithelioma / mixed tumor
  4. Measurable disease as per RECIST 1.1.
  5. Subject has received either:

    • No prior chemotherapy for current sarcoma, or
    • A single course of gemcitabine and/or docetaxel as adjuvant therapy that was completed at least 6 months prior to planned first dose
  6. ECOG Performance Status of 0 - 2.
  7. Adequate cardiac function:

    • LVEF above the institution's lower limit of normal
    • QTcF ≤ 450 msec for males or 470 msec for females.
  8. Willing and able to provide written informed consent.
  9. Male and female subjects must agree to use a highly reliable method of birth control for the duration of the study.
  10. Women of childbearing potential must have a serum pregnancy test performed within 28 days prior to the first day of study drug dosing.

Exclusion Criteria:

  1. Sarcomas arising from bone or cartilage, e.g. chondrosarcoma, osteosarcoma, chordoma.
  2. Subject is eligible for a potentially curative therapy.
  3. Prior primary chemotherapy.
  4. Prior radiotherapy to > 25% of bone marrow volume.
  5. Treatment within 28 days prior to Dose 1 with:

    • Palliative surgery or radiotherapy.
    • Approved anticancer therapy including chemotherapy or immunotherapy.
    • Contraindicated treatments noted in the product labelling for doxorubicin, including trastuzumab and inhibitors and inducers of CYP3A4, CYP2D6, or P-gp.
    • An investigational therapy.
    • Any major surgery (e.g. requiring general anesthesia).
  6. Inadequate bone marrow, liver, and renal function, as assessed by the following laboratory parameters:

    1. Absolute neutrophil count (ANC) < 1,500/mm3.
    2. Platelet count < 100,000/mm3.
    3. Total bilirubin > 1.5×ULN (upper limit of normal).
    4. ALT and AST > 2.5×ULN. For patients with documented liver metastases, ALT and AST > 5×ULN.
    5. Serum creatinine > 1.5 x ULN.
    6. International Normalized Ratio (INR) and activated partial thromboplastin time [PTT] ≥ 1.5×ULN, if not therapeutically anticoagulated.
    7. Serum albumin < 3.0 gm/dL.
  7. Congestive heart failure > Class II New York Heart Association Functional Classification, current pericarditis, myocardial infarction within 6 months, or symptomatic coronary artery disease.
  8. Unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol.
  9. Active infection requiring systemic antibacterial/antibiotic, antifungal, or antiviral therapy.
  10. Documented metastases to brain or meninges.
  11. Any malignancy other than soft tissue sarcoma within the last 5 years prior to screening, with the exception of cervical carcinoma in situ, basal cell carcinoma, or superficial bladder tumors that have been successfully and curatively treated with no evidence of recurrent or residual disease.
  12. Body surface area (BSA) ≥ 2.4 m2.
  13. Currently pregnant or nursing.
  14. Known allergy to any of the study drugs or their excipients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02267083


Locations
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Iowa
University of Iowa Holden Comprehensive Cancer Center
Iowa City, Iowa, United States, 52242
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Pennsylvania
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Sponsors and Collaborators
Gem Pharmaceuticals
Investigators
Principal Investigator: Mohammed Milhem, MD University of Iowa Holden Comprehensive Cancer Center

Responsible Party: Gem Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02267083     History of Changes
Other Study ID Numbers: GPX-150-002
First Posted: October 17, 2014    Key Record Dates
Results First Posted: January 10, 2018
Last Update Posted: January 10, 2018
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Gem Pharmaceuticals:
soft tissue sarcoma

Additional relevant MeSH terms:
Sarcoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action